Article

State Offers Incentives to Get Docs Online

Pennsylvania is hoping an offer of free software and a new customer reward will get smaller healthcare providers to turn off their fax machines and to switch to secure, encrypted email to share patient information.

It's part of a national program designed to provide a halfway point for providers that can't afford the infrastructure to connect with a healthcare information exchange.

Read the full story: http://tinyurl.com/bw7rsfp

Source: MedPage Today

Related Videos
Christine Funke, MD
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
CK Wang, MD, COTA
Pieter Sonneveld, MD, PhD
Harry Travis sitting for a video interview
Naim Alkhouri, MD
Antoine Keller, MD
Pieter Sonneveld, MD, PhD
Related Content
The findings also show that ropeginterferon alfa-2b is an effective therapy for molecular response in early polycythemia vera. | Image credit: fotogurmespb.- stock.adobe.com
May 23rd 2025

Molecular Response to Therapy Linked With Event-Free Survival in PV

Jared Kaltwasser
New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.
managed care cast logo
May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS
Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com
May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser
Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor
The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.
In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com
May 22nd 2025

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

Rose McNulty
Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo